Background: Evidence points to the pivotal role of vitamin D in the pathogenesis of metabolic syndrome (MetS), including deterioration of the endogenous endothelial repair system.
Background
Metabolic syndrome (MetS) is a cluster of cardiovascular (CV) risk factors, including central obesity, glucose homeostasis, insulin resistance (IR), hypertension and atherogenic dyslipidemia (1) . Recent studies have shown that patients with MetS have an almost two-fold increased risk of CV disease and CV events, asymptomatic atherosclerosis, all cause and CV death rate (2, 3) .
There is evidence regarding the pivotal role of vitamin D in the pathogenesis of CV disease in dysmetabolic states (4) . Serum concentrations 25(OH)D3 provide a reliable indicator of body vitamin D status. Low serum 25(OH)D3 levels have been directly linked to MetS, whereas the overall risk of MetS in the general population is probably not associated with 25(OH)D3 concentrations (5) (6) (7) . Vitamin D deficiency (defined as a serum 25(OH)D3 level below 20 ng/mL) is associated with IR, decreased insulin secretion by pancreatic beta-cells, inflammation, lower circulating adiponectin levels, and activation of the renin-angiotensin system (8, 9) . In addition, abdominal obesity, hypertension, endothelial dysfunction and dyslipidemia have exhibited a close association with low levels of 25(OH)D3 (10, 11) . The 25(OH)D3 serum may act through the vitamin D receptor (VDR), which mediates calcium efflux into target cells and attenuates the secretion of inflammatory cytokines via direct stimulation of transcription factor nuclear factor-κB (NF-κB) (12) . VDR and the 1α-hydroxylase enzyme, which catalyzes the conversion of 25(OH)D3 to 1,25-dihydroxyvitamin D (1,25(OH)2D) and is expressed on the surface of several cell types, may contribute to multiple metabolic regulation of target cells including progenitor cells (13) . Finally, oxidative stress, inflammatory cytokines, and vitamin D status mediated through several epigenetic mechanisms may change the functionality of progenitor endothelial/mononuclear cells.
The role of vitamin D in the recruitment and differentiation of progenitor mononuclear cells, which are involved in the pathophysiology of metabolic states, remains controversial (14, 15) . Indeed, dysfunction of progenitor mononuclear cells may play a prominent role in the worsening of endothelium reparation due to direct endothelium damage, endothelial dysfunction, microvascular inflammation, and oxidative stress (16) . In contrast, endothelial function may be impaired due to altered maturation/commitment of progenitor mononuclear cells rather than as the result of a simple decrease in their production in the bone marrow. This process may be under the control of 25(OH)D3 (17) . Recent studies have confirmed the relationship between 25(OH)D3 and depleted numbers of circulating endothelial progenitor cells in diabetes mellitus (18, 19) . However, the relationship between the number of circulating progenitor mononuclear cells in MetS patients and 25(OH)D3 levels is not yet fully clear.
Objectives
The objective of the study was to investigate links between 25(OH)D3 concentrations and the number of circulating progenitor mononuclear cells in MetS individuals.
Methods

Study Design and the Study Population
This cross-sectional study involved 47 patients with MetS who were examined within winter months (between December 2012 and February 2013, December 2013 and February 2014, and between December 2014 and February 2015) to minimize seasonal bias. The study protocol was approved by the local ethics committee review board (IRB # 3/2010) of the State Medical University of Zaporozhye (Ukraine) prior to the study commencing. The study complied with the Declaration of Helsinki and voluntary written informed consent was obtained from all patients included in this study.
We enrolled MetS subjects without known type 2 diabetes mellitus (T2DM), typical angina symptoms, or exiting coronary artery disease, and for whom we did not have angiographic evidence of asymptomatic atherosclerosis obtained by contrast-enhanced multi-spiral tomography angiography, which was provided prior to taking part in the study.
MetS was diagnosed based on the national cholesterol education program adult treatment panel III criteria (20) . Patients were enrolled in the MetS cohort when at least three of the following components were defined: waist circumference of ≥ 90 cm or ≥ 80 cm for men and women, respectively; HDL-C levels of < 1.03 mmol/L or < 1.3 mmol/L for men and women, respectively; triglycerides levels of ≥ 1.7 mmol/L; blood pressure at ≥ 130/85 mmHg, current exposure to antihypertensive drugs; or fasting plasma glucose levels of ≥ 5.6 mmol/L.
Anthropometric Measurements
Anthropometric measurements including height, body weight, and waist circumference were made using standard procedures after an overnight fast following the first visit. Body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared. Systolic and diastolic blood pressure was measured using an automatic blood pressure monitor (Omron, Japan).
Current Smoking Status
Current smoking was defined as consumption of one cigarette daily for three months.
Treatment and Concomitant Medications
Subjects with MetS had been treated by the adoption of life-style and diet modifications. As a result, metformin was given to 12 patients.
Calculation of the Glomerular Filtration Rate (GFR)
The glomerular filtration rate (GFR) was calculated using the CKD-EPI formula (21).
Determining Insulin Resistance (IR)
IR was assessed by HOMA-IR (22) using the following formula:
HOMA-IR (mmol/L × µU/mL) = fasting glucose (mmol/L) × fasting insulin (µU/mL)/22.5 IR was determined when the estimated HOMA-IR value was over 2.77 mmol/L × µU/mL, as defined previously (23).
Measurement of Circulating Biomarkers
To determine circulating biomarkers, blood samples were collected at baseline in the morning (between 7 and 8 a.m.) and placed in cooled silicone test tubes to which 2 mL of 5% Trilon B solution were added. They were then centrifuged on permanent cooling at 6000 rpm for 3 minutes. Plasma was collected and refrigerated immediately to be stored at a temperature of -70°C.
Serum adiponectin, the receptor activator of nuclear factor κB ligand (RANKL), and osteoprotegerin (OPG) were measured by high-sensitive enzyme-linked immunosorbent assays using commercial kits (R and D Systems GmbH, Wiesbaden-Nordenstadt, Germany) according to the manufacturers' recommendations. The inter-assay coefficients of variation were as follows: adiponectin 5%; RANKL 7.0%; and OPG 8.2%. We measured hs-CRP with a commercially available standard kit (R and D Systems GmbH, WiesbadenNordenstadt, Germany). The intra-assay and inter-assay coefficients of variation were < 5%.
Fasting insulin levels were measured by a doubleantibody sandwich immunoassay (Elecsys 1010 analyzer, F. Hoffmann-La Roche diagnostics, Mannheim, Germany). The intra-assay and inter-assay coefficients of variation were < 5%. The lower detection limit of insulin levels was 1.39 pmol/L.
Concentrations of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and HDL-C were measured by the enzymatic colorimetric method according to the standardized methodology on a Beckman Synchron LX20 chemistry analyzer.
Measurement of Plasma 25-hydroxy Vitamin D3 (25(OH)D3)
Circulating levels of 25(OH)D3 were measured using an ELISA kit (BG Medicine, Germany). Plasma 25(OH)D3 levels above 100 nmol/L are defined as the optimal vitamin D status and levels between 50 and 100 nmol/L are defined as adequate. Serum levels of 25(OH)D below 50 nmol/L suggest an inadequate vitamin D status, whereas values below 30 nmol/L indicate vitamin D deficiency.
Assay of Circulating Mononuclear Progenitor Cell Subsets
The FCT was used to consistently identify circulating cell subsets, which depend on the expression of CD45, CD34, CD14, Tie-2, and CD309 (VEGFR2), using the highdefinition fluorescence activated cell sorter (HD-FACS) methodology (24) . Accordingly, the cells were labeled on the basis of their forward scatter characteristic (FSC) and side scatter characteristic (SSC) profiles. Using standardized and calibrated instruments, sensitivity and fluorescence and light scatter resolution were determined according to the standard protocol (25) .
The cells were directly stained and analyzed for phenotypic expression of surface proteins using anti-human monoclonal antibodies, including anti-CD45 FITS (BD biosciences, San Jose, CA, USA), anti-CD34 FITS (BD Biosciences), anti-VEGFR-2 known as anti-CD309 (BD Biosciences), antiTie2 (BD Biosciences) and anti-CD14 (BD Biosciences). The fluorescence minus one technique was used to provide negative controls and to establish positive stain boundaries. After lysis of erythrocytes with UTILIZE wash solution, the samples were centrifuged at 200 × g for 15 minutes. The samples were then washed twice with phosphate buffer solution (PBS) and fixed immediately. Double-and triple-positive events were determined using Boolean principles (and, not, or, etc.).
Determination of Circulating Progenitor Mononuclear Cells of Endothelial Origin
Circulating mononuclear progenitor cells were defined as CD34/D309 (VEGFR2) positive cells lacking CD45 expression. From each tube 500,000 events were analyzed. For CD14 + populations, co-expression with Tie-2 and/or VEGFR-2 was determined using quadrant analysis. Standardized cell counts were presented as a percentage of the total of the white blood cell count, identified as the total number of all CD45 + cells. producibility of mononuclear progenitor cell measurements was 3.5% using the standard protocol.
Statistical Analysis
Statistical analysis of the results was carried in SPSS for Windows (IBM Corp. Released 2013. IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp, USA). The data were presented as mean (M) and standard deviation (± SD) or a 95% confidence interval (CI), as well as median and in the 25% -75% interquartile range (IQR). The sample size (n = 47) was determined statistically by power analysis methods, taking into account an anticipated effect size (f2) equal to 0.25, a desired probability level of 0.05, a statistical power level of 0.8, and 3 predictors. To compare the main parameters of the patient cohorts, a two-tailed Student t-test or the Mann-Whitney U test were used. To compare categorical variables between groups, a Chi2 test (χ 2 ) and Fisher exact test were used. Predictors of depleted numbers of progenitor mononuclear cells in MetS patients were examined in univariate and multivariate log-linear regression analysis. We calculated the observed power for multiple regression, given the observed probability level, the number of predictors, the observed R 2 , and the sample size (n = 47). C-statistics, integrated discrimination indices (IDI), and net-reclassification improvement (NRI) were used for prediction performance analyses. A two-tailed probability value of < 0.05 was considered as significant.
Results
The mean age of the 47 MetS patients (30 males, 63.3%) was 48.34 years. The baseline characteristics of the patients are listed in Table 1 . Regarding CV risk factors, 68% of the patients were hypertensive, 55.3% of subjects exhibited dyslipidemia, and 34% were smokers. The mean GFR was 92.5 mL/minute/1.73 m 2 . Regarding 25(OH)D3 levels, MetS patients from entire group were divided into four cohorts comprising patients with 25(OH)D3 levels above 100 nmol/L (n = 10), patients with levels between 50 and 100 nmol/L (n = 12), patients with levels between 30 and 50 nmol/L (n = 14), and patients with levels below 30 nmol/L (n = 11), defined as adequate vitamin D status, inadequate vitamin D status, insufficient vitamin D and vitamin D deficiency, respectively. The mean plasma levels of 25(OH)D3 in each MetS cohort are presented in Figure 2 .
The patients with vitamin D deficiency appear to be have a higher age (P = 0.046) and frequently-defined dyslipidemia (P = 0.044) ( Table 1) . Therefore, there was a sufficient difference between cohorts in terms of HbA1c (P = 0.038), HOMA-IR (P = 0.042), triglycerides (P = 0.044), osteoprotegerin (P = 0.028), adiponectin (P = 0.018), HDL-C (P = 0.036), and CD14 + D309 + Tie-2 + cells ( Table 2 ).
The univariate linear regression was used to determine the link between plasma levels of 25(OH)D3, the numbers of progenitor mononuclear cells, CV risk factors, and other biomarkers. The data showed that plasma levels of (Table 4) . When we used another model based on entering continuous variables, osteoprotegerin, hs-CRP, and adiponectin did not significantly improve the predictive model based on the vitamin D deficiency status. In the patient study population for category-free NRI, 3% of events (P = 0.16) and 4% of non-events (P = 0.12) were correctly reclassified by the addition of circulating inflammatory biomarkers to the base model.
Discussion
The findings of the study show that vitamin D deficiency was a statistically significant predictor for decreased numbers of proangiogenic progenitor mononuclear cells, labelled as CD14 + D309 + Tie-2 + cells in MetS patients without known CV disease. From current knowledge, the depletion of proangiogenic subsets of circulating progenitor mononuclear cells is a marker of asymptomatic atherosclerosis and CV events (26, 27) . There is large body of evidence regarding a close inverse association between serum levels of inflammatory biomarkers (osteoprotegerin, hs-CRP, and adiponectin) and numbers/functionality of proangiogenic progenitor mononuclear cells in dysmetabolic patients with known CV disease (28) . In diabetics, oxidative stress components, osteoprotegerin, hs-CRP, and adiponectin may enhance the epigenetic mechanisms of cell function regulation, leading to methylation-related changes to the gene promoter region and DNA damage to target cells (29, 30) . These pathways remain triggers of angiogenic progenitor mononuclear cell dysfunction (31, 32) . They are considered as b Categorical variables are expressed as numbers (n) and percentages (%). c P-value is a comparison of mean or median variables between both cohorts (ANOVA test).
clues in forming metabolic memory, which mediates manifestation and progression of CV disease in diabetes (33) . 25(OH)D3 may regulate the functionality of angiogenic progenitor mononuclear cells and attenuate their reparative capability (34, 35) . Taken together, the findings suggest that vitamin D deficiency could coordinate the altered repair ability of progenitor mononuclear cells and inflammation in MetS. We speculated that 25(OH)D3 could be involved in the pathogenesis of MetS and CV complications, affecting the molecular mechanisms of the proliferation, differentiation, and function of angiogenic progenitor mononuclear cells. We also noticed that vitamin D status was closely associated with age, BMI, dyslipidemia, and HOMA-IR, as well as the serum levels of inflammatory biomarkers (osteoprotegerin, hs-CRP, and adiponectin). Interestingly, after adjustment for BMI and age, plasma levels of 25(OH)D3 continued to be linked to the numbers of angiogenic progenitor mononuclear cells and inflammatory biomarkers.
Recent studies have shown that 25(OH)D3 plays a pivotal role in the formation of capillary-like structures, which are considered a definite step in angiogenesis de novo (36, 37) . Because mononuclear progenitor cells participate in maintaining endothelial integrity and vascular homeostasis, 25(OH)D3 deficiency may contribute to vascular dysfunction in MetS through altered differentiation of mononuclear progenitors into mature endothelial cells (38) . The results of our study showed that deficiency of 25(OH)D3 may be associated with impaired progenitor mononuclear patterns in MetS patients by enhancing IR development and low-grade inflammation.
Probable glucose toxicity via the epigenetic effect may contribute to IR in mononuclear progenitor cells (39) . Indeed, a negative impact of 25(OH)D3 as an inhibitor of neovascularization and cell migration on the pattern of angiogenic progenitor mononuclear cells may occur when up-regulated inflammatory cascade cytokines are present. It is difficult to explain why 25(OH)D3 deficiency can lead to controversial effects among these settings. It has been reported that most metabolically healthy obese individuals do not exhibit a high risk of diabetes development where IR is present (40) . In addition, the numbers of angiogenic progenitor mononuclear cells appear to be increased in the MetS patient population (41) . In contrast, MetS individuals have shown decreased levels of progenitor mononuclear cells with angiogenic immune phenotypes (42) , which independently predict CV and atherosclerotic disease progression (43, 44) . This may suggest that vitamin D deficiency in MetS subjects could lead to an exacerbation of inflammation through changes to the endothelium repair system, i.e., angiogenic progenitor mononuclear cells. The causative relationship between vitamin D deficiency and depleted numbers of circulating progenitor mononuclear cells with angiogenic immune pheno- b Categorical variables are expressed as numbers (n) and percentages (%). c P-value is a comparison of mean or median variables between both cohorts (ANOVA test). types requires more investigation in the future.
In conclusion, we found that low levels of 25(OH)D3 may be associated with depleted numbers of proangiogenic progenitor mononuclear cells in MetS patients. Further research is required to explain the link between vitamin D status and the numbers of circulating angiopoetic progenitor mononuclear cells in MetS patients without known CV disease. 
Study Limitations
This study has some limitations. Due to the small size of the study population we cannot exclude the possibility that other immune phenotypes of progenitor mononuclear cells might be affected by vitamin D status. Despite the statistically significant findings regarding the prediction of biomarkers, it seems that the results become clinically relevant after adjustments for age and BMI. The predictive role of age and BMI needs to be carefully explored. However, the authors believe that these restrictions should have no significant impact on the interpretation of the study data.
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